Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer

Table 1

(a) Baseline study population characteristics n = 44.

	Patients
Gender
Male	34/44	77%
Female	10/44	22%
Median Age range	77
Histology
Adenocarcinoma	34/44	77%
Squamous	8/44	18%
unspecified NSCLC	2/44	4%
smoke status
Current smoker	3/44	6%
Former smoker	35/44	79%
never smoker	6/44	13%
ECOG PS: 1	24/44	54%
ECOG PS ≥2	20/44	45%
No. of chemothepy lines
Line I chemotherapy	6/44	13%
Line II chemotherapy	38/44	87%
Response Rate
SD	16/44	36%
PR partial response	12/44	27%
PD	16/44	36%
Clinical benefit	28/44	63%
ORR	27% (CI 18-36%)

(b) PFS and OS

PFS mean months	9
Overall survival medianmonths	12
PFS HR under 75/over 75 years	0.72	<0.05